Rutschow S., Leschka S., Westermann D. et al. (2010)
Left ventricular enlargement in coxsakievirus-B3 induced myocarditis
ongoing inflammation and an imbalance of the matrix degrading system.
Eur. Pharmacol., Vol. 630: 145—151. doi: 10.1016/j.ejphar.2009.12.019.
67.
Sakibuzzaman M., Fariza T.T., Rahman S.M. et al. (2020)
A Clinical Review of COVID-19 Associated Myocarditis. Archives of Clin-
ical and Biomedical Research, Vol. 4(5): 468–480. doi: 10.26502/
acbr.50170119.
68.
Sawalha K., Abozenah M., Kadado A.J. et al. (2021) Sys-
tematic Review of COVID-19 Related Myocarditis: Insights on Manage-
ment and Outcome. Cardiovasc. Revasc. Med., Vol. 23: 107–113. doi:
10.1016/j.carrev.2020.08.028
69.
Schultheiss H.P., Escher F. (2018) Chapter «Tratment of myo-
carditis» in ESC CardioMed (3 edn.) edited by Camm A.J., Luscher T.F.,
Maurer G., Serruys P.W. Oxford University Press. DOI: 10.1093/
med/9780198784906.003.0368.
70.
Schultheiss H.P., Piper C., Sowade O. et al. (2016) Be-
taferon in chronic viral cardiomyopathy (BICC) trial: effects ofinter feron-b
treatment in patients with chronic viral cardiomyopathy. Clin. Res. Car-
diol., Vol. 105: 763–769. doi: 10.1007/s00392–016–0986–9.
71.
Seferovic P.M., Polovina M., Bauersachs J. et al. (2019)
Heart failure in cardiomyopathies: a position paper from the Heart Failure
Association of the European Society of Cardiology. European Journal of
Heart Failure, Vol. 21: 553–576. doi: 10.1002/ejhf.1461.
72.
Shah Z., Mohammed M., Vuddanda V. et al. (2019) Na tional
Trends, Gender, Management, and Outcomes of Patients Hospitalized
for Myocarditis. Am. J. Cardiol., Vol. 124(1): 131–136. doi: 10.1016/j.
amjcard.2019.03.036.
73.
Sinagra G.F., Anzini M., Pereira N.L. et al. (2016) Myocar-
ditis in clinical practice. Mayo Clin. Proc., Vol. 91 (9): 1256–1266. doi:
10.1016/j.mayocp.2016.05.013.
74.
